ENDOVASCULAR TREATMENT OF CAROTID ARTERY STENOSIS

Retrospective study of 79 patients treated with stenting and angioplasty with and without cerebral protection devices

Eduardo Noda Kihara1, Mario Sergio Duarte Andrioli1, Eliova Zukerman2, Mario Fernando Prieto Peres2, Pedro Paulo Porto Júnior2, Paulo Hélio Monzillo2, Ivan Hideyo Okamoto2, Ayrton Roberto Massaro2, José Carlos Zirretta3.

ABSTRACT - We evaluate the results of stenting and angioplasty on carotid bifurcation stenotic lesions using protection systems, emphasizing the indications and technical aspects. Seventy-nine patients, mean age 64.5 years were treated from February, 1998 to March, 2003. All patients were included in NASCET study criteria. Forty three patients were treated without the protection systems and thirty six were treated with carotid protection filtering system (Angioguard, EPI). Technical success and 6-months carotid ultrasound follow-up showing stent patency were achieved in all patients. One major stroke and one death due to intracranial reperfusion bleeding occurred in patients treated without cerebral protection devices. Only one patient presenting hyper perfusion syndrome improving after 7 days, was found in the group treated with the cerebral protection filter mechanism, no other neurologic symptom or death occurred in this group. Stenting and angioplasty with protection systems for thromboembolic debris is a safe endovascular method to treat stenotic lesions in the carotid bifurcation with low morbidity and mortality.

KEY WORDS: carotid artery stent, carotid artery atherosclerosis, endovascular therapy.

Stroke is one of the leading causes of death worldwide. More than 500,000 new strokes occur annually in the United States, and it has been estimated that carotid artery disease may be responsible for 20% to 30% of them. The annual stroke event rate for asymptomatic patients with hemodynamically sig-
nificant carotid artery stenosis ranges from 2% to 5%[^2]. Carotid artery stenosis usually is identified after transient ischemic attack (TIA), but for many patients, cerebral infarction caused by artery-to-artery embolism or carotid occlusion is the initial event. Progression of asymptomatic carotid artery stenosis to occlusion is unpredictable and can be disastrous; at the time of occlusion, disabling stroke may occur in 20% of patients, and thereafter in 1.5% to 5% annually[^3]. The North American Symptomatic Carotid Endarterectomy Trial[^4] (NASCET), showed beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis (70 - 99%). The cumulative risk of any ipsilateral stroke at two years were 26 percent in the 331 medical patients and 9 percent in the 328 surgical patients an absolute risk reduction of 17 %. For a major or fatal ipsilateral stroke, the corresponding estimates were 13.1% versus 2.5 %, an absolute risk reduction of 10.6%[^4]. No beneficial has been found in less than 50% stenosis[^5]. Since then, carotid endarterectomy (CEA) has been one of the most commonly performed peripheral vascular procedures and has been considered the most effective treatment for stroke prevention in patients with high-grade symptomatic or asymptomatic carotid artery disease (CAD)[^6,^7].

In the past few years carotid angioplasty and stenting (CAS) has been proposed as an alternative endovascular treatment[^8,^9]. Despite an increasing enthusiasm for the application of CAS in the treatment of CAD and an abundant literature on case series of CAS, only three studies have been published to date, which directly compare CEA with CAS[^10-12]. In CAVATAS, the first completed, prospective multicenter trial comparing endovascular versus surgical treatment for CAD, a similar major risk and effectiveness for CAS compared with carotid surgery has recently been reported[^10].

Percutaneous carotid stenting is accomplished with an increased incidence of microemboli, as shown by transcranial Doppler monitoring[^13]. These emboli are associated with a higher neurological complication rate and are also recognized as a potential cause of periprocedural stroke during endarterectomy[^4].

Cerebral protection with filter devices during carotid artery stenting has been recently shown better results[^15-19].

Multiple cerebral protection systems are available, from occlusion balloon protection techniques to filter devices placed above the lesion. The occlusion balloon system is advanced across the area of stenosis, with a small caliber guidewire, angioplasty is performed with the occlusion balloon inflated. The angioplasty catheter (with its balloon deflated) is advanced just proximal to the occlusion balloon. Angioplasty debris is then flushed into the external carotid circulation, with the occlusion balloon deflated, avoiding the fragments from reaching the distal circulation[^15-17]. The filter protection mechanism allows red blood cells flow, blocking only higher than 100 micra particules. Stenotic lesions can be treated even if severe contralateral disease is present[^18,^19].
This study objective is to describe our experience in the percutaneous endovascular treatment of internal carotid artery stenosis with angioplasty and stenting with and without cerebral protection devices.

METHOD

Seventy nine patients were treated, 49 men, 30 women. Age ranged from 57 to 72 years (mean 64.5). Sixty three patients were symptomatic with higher than 60% stenosis and sixteen asymptomatic patients with higher than 80% stenosis were treated, 43 patients were treated without protection mechanisms, from February, 1998 to July, 2001. After August, 2001, all the procedures were performed with the angio guar or EPI filter16,17.

All patients had clinical, neurological, laboratory and neuroimaging evaluation previously to the procedure. Antiplatelet aggregation therapy was started at least 72 hours before it. Local anesthesia at the femoral artery, sedation and anticoagulation with heparin were done during the procedure. Atropine sulfate was administered intravenously in order to avoid any abnormal vagal response after carotid sinus stimulus during the stenting and angioplasty. Angiography was done to assess the intracranial circulation. Under fluoroscopy (roadmap) the protection system was introduced throughout the stenotic lesion, avoiding traumas and false tract to the artery wall. In severe stenosis, a pre-dilatation with low profile balloon was done.

After opening the filter device above the lesion, stenting implantation was performed. The balloon was inflated at the stenotic atherome plaque level, decreasing its stenosis after deflation. During the procedure, the protection device was kept open for an eventual emboli trapping. A completion angiogram was then obtained, for a comparison to previous images. Mechanical reperfusion or thrombolisis were available if necessary. Patients were continuously monitored at the intensive care unit for the first 48 hours. Antiplatelet therapy was prescribed. Tirofiban, a glicoprotein IIa-IIIb blocker was used in severe cases (irregular lesions, smoking patients). In one patients with pos surgical restenosis Abciximab was utilized (19). Carotid doppler ultrasound follow-up was obtained until 6 months after procedure.

RESULTS

Complete stenosis restauration was obtained in all 79 patients treated. In the initial group (43 patients) treated without the protection system, one stroke occurred 24 hours after treatment, and one patient died due to cerebral haemorrhage. In the subsequent 36 patients treated with the filter device, only one patient with severe stenosis presented with hyperfusion syndrome, discharged 9 days after the procedure. No major neurological deficits happened in the patients treated with the filter device.

Carotid sinus vagal reaction occurred in 5 patients after the first 12 hours, the patients were treated with atropine. At the 6-months carotid Doppler follow-up no restenosis were found. Six patients had 12-months angiography follow-up without intraluminal changes (Figs 1, 2, and 3).

DISCUSSION

We observed in our case series a trend to less complications in patients treated with the cerebral protection with the filter device, however a definite answer for the true difference in efficacy and complications after percutaneous treatment versus endarterectomy has yet to be determined. Ongoing trials such as the Sapphire and Archer trials will help clarifying the issue. The CREST study is following 2500 patients treated with endarterectomy or angioplasty and stenting of moderate to severe carotid stenosis patients20.

Other multicenter worldwide study enrolled 6327 patients treated with angioplasty and stenting without cerebral protection devices, showed a technical success in 98.4% of cases. Ischaemic strokes occurred in 2.7%, those with neurological deficits lasting more than 30 days in 1.3%, mortality rate was 0.7%. Restenosis rate in 12-months follow up was 5.56%. A recent study of 2038 patients treated with angioplasty and stenting with cerebral protection devices showed a significant reduction in strokes and mortality rates21.
In conclusion, percutaneous stenting and angioplasty with cerebral protection devices for carotid stenotic lesions, in symptomatic with higher than 60% stenosis and asymptomatic patients with higher than 80% stenosis, is a safe and efficient method of treatment with low morbidity and mortality. Carotid protection devices allowed maintenance of cerebral blood flow during the procedure reducing trombo embolic complications and morbidity rates.

REFERENCES